BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prins GH, Olinga P. Potential implications of COVID-19 in non-alcoholic fatty liver disease. Liver Int. 2020;40:2568. [PMID: 32306495 DOI: 10.1111/liv.14484] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Morgan K, Samuel K, Vandeputte M, Hayes PC, Plevris JN. SARS-CoV-2 Infection and the Liver. Pathogens. 2020;9. [PMID: 32486188 DOI: 10.3390/pathogens9060430] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
2 Díaz LA, Idalsoaga F, Cannistra M, Candia R, Cabrera D, Barrera F, Soza A, Graham R, Riquelme A, Arrese M, Leise MD, Arab JP. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data. World J Gastroenterol 2020; 26(48): 7693-7706 [PMID: 33505145 DOI: 10.3748/wjg.v26.i48.7693] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
3 Przekop D, Gruszewska E, Chrostek L. Liver function in COVID-19 infection . World J Hepatol 2021; 13(12): 1909-1918 [DOI: 10.4254/wjh.v13.i12.1909] [Reference Citation Analysis]
4 Anjum MR, Chalmers J, Hamid R, Rajoriya N. COVID-19: Effect on gastroenterology and hepatology service provision and training: Lessons learnt and planning for the future. World J Gastroenterol 2021; 27(44): 7625-7648 [PMID: 34908803 DOI: 10.3748/wjg.v27.i44.7625] [Reference Citation Analysis]
5 Xu Y, Yang X, Bian H, Xia M. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. Lipids Health Dis 2021;20:126. [PMID: 34602072 DOI: 10.1186/s12944-021-01564-z] [Reference Citation Analysis]
6 Cava C, Bertoli G, Castiglioni I. A protein interaction map identifies existing drugs targeting SARS-CoV-2. BMC Pharmacol Toxicol 2020;21:65. [PMID: 32883368 DOI: 10.1186/s40360-020-00444-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
7 Hamid S, Alvares da Silva MR, Burak KW, Chen T, Drenth JPH, Esmat G, Gaspar R, LaBrecque D, Lee A, Macedo G, McMahon B, Ning Q, Reau N, Sonderup M, van Leeuwen DJ, Armstrong D, Yurdaydin C. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. J Clin Gastroenterol. 2021;55:1-11. [PMID: 33230011 DOI: 10.1097/mcg.0000000000001459] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
8 Sjöstedt N, Neuhoff S, Brouwer KLR. Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis. Clin Pharmacol Ther 2021;109:676-87. [PMID: 32897538 DOI: 10.1002/cpt.2037] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Huang YK, Li YJ, Li B, Wang P, Wang QH. Dysregulated liver function in SARS-CoV-2 infection: Current understanding and perspectives. World J Gastroenterol 2021; 27(27): 4358-4370 [PMID: 34366609 DOI: 10.3748/wjg.v27.i27.4358] [Reference Citation Analysis]
10 Miele L, Napodano C, Cesario A, De Magistris A, Pocino K, Basile U, Rapaccini GL, Gasbarrini A, Grieco A. COVID-19, adaptative immune response and metabolic-associated liver disease. Liver Int 2021;41:2560-77. [PMID: 34555255 DOI: 10.1111/liv.15061] [Reference Citation Analysis]
11 Luo J, Liang S, Jin F. Gut microbiota in antiviral strategy from bats to humans: a missing link in COVID-19. Sci China Life Sci 2021;64:942-56. [PMID: 33521857 DOI: 10.1007/s11427-020-1847-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Jha NK, Sharma C, Hashiesh HM, Arunachalam S, Meeran MN, Javed H, Patil CR, Goyal SN, Ojha S. β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19. Front Pharmacol 2021;12:590201. [PMID: 34054510 DOI: 10.3389/fphar.2021.590201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sahu S, Patil CR, Kumar S, Apparsundaram S, Goyal RK. Role of ACE2-Ang (1-7)-Mas axis in post-COVID-19 complications and its dietary modulation. Mol Cell Biochem 2021. [PMID: 34655418 DOI: 10.1007/s11010-021-04275-2] [Reference Citation Analysis]
14 Sy-Janairo ML, Y Cua IH. Association of metabolic-associated fatty liver disease and risk of severe coronavirus disease 2019 illness.JGH Open. 2020;. [PMID: 33363258 DOI: 10.1002/jgh3.12465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 de Jesus RP, de Carvalho JF, de Oliveira LPM, Cunha CM, Alves TCHS, Vieira STB, Figueiredo VM, Bueno AA. Metabolic and nutritional triggers associated with increased risk of liver complications in SARS-CoV-2. World J Hepatol 2022; 14(1): 80-97 [DOI: 10.4254/wjh.v14.i1.80] [Reference Citation Analysis]
16 Lamadrid P, Alonso-Peña M, San Segundo D, Arias-Loste M, Crespo J, Lopez-Hoyos M. Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity. Front Immunol 2021;12:651728. [PMID: 33859644 DOI: 10.3389/fimmu.2021.651728] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med. 2020;77:18-24. [PMID: 32507608 DOI: 10.1016/j.ejim.2020.05.035] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 17.5] [Reference Citation Analysis]
18 Fierro NA. COVID-19 and the liver: What do we know after six months of the pandemic? Ann Hepatol 2020;19:590-1. [PMID: 32956871 DOI: 10.1016/j.aohep.2020.09.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
19 Singh A, Hussain S, Antony B. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis. Diabetes Metab Syndr 2021;15:813-22. [PMID: 33862417 DOI: 10.1016/j.dsx.2021.03.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
20 Ali FEM, Mohammedsaleh ZM, Ali MM, Ghogar OM. Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. World J Gastroenterol 2021; 27(15): 1531-1552 [PMID: 33958841 DOI: 10.3748/wjg.v27.i15.1531] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wu H, Liu S, Luo H, Chen M. Progress in the Clinical Features and Pathogenesis of Abnormal Liver Enzymes in Coronavirus Disease 2019. J Clin Transl Hepatol 2021;9:239-46. [PMID: 34007806 DOI: 10.14218/JCTH.2020.00126] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Ahmed M, Ahmed MH. Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic. World J Clin Cases 2021; 9(17): 4133-4142 [PMID: 34141776 DOI: 10.12998/wjcc.v9.i17.4133] [Reference Citation Analysis]
23 Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur J Clin Invest. 2020;50:e13338. [PMID: 32589264 DOI: 10.1111/eci.13338] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 12.5] [Reference Citation Analysis]
24 Mair M, Singhavi H, Pai A, Singhavi J, Gandhi P, Conboy P, Baker A, Das S. A Meta-Analysis of 67 Studies with Presenting Symptoms and Laboratory Tests of COVID-19 Patients. Laryngoscope. 2021;131:1254-1265. [PMID: 33068023 DOI: 10.1002/lary.29207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
25 Chen JC, Xie TA, Lin ZZ, Li YQ, Xie YF, Li ZW, Guo XG. Identification of Key Pathways and Genes in SARS-CoV-2 Infecting Human Intestines by Bioinformatics Analysis. Biochem Genet 2021. [PMID: 34787756 DOI: 10.1007/s10528-021-10144-w] [Reference Citation Analysis]
26 Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, Judge R, Soubieres A, Middleton P, Daunt A, Perez-Guzman P, Selvapatt N, Lemoine M, Dhar A, Thursz MR, Nayagam S, Manousou P. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 2020;15:e0240400. [PMID: 33031439 DOI: 10.1371/journal.pone.0240400] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
27 Parlak S, Çıvgın E, Beşler MS, Kayıpmaz AE. The effect of hepatic steatosis on COVID-19 severity: Chest computed tomography findings. Saudi J Gastroenterol 2021;27:105-10. [PMID: 33642355 DOI: 10.4103/sjg.sjg_540_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]